CD8A and systemic lupus erythematosus: Targeting IL-21 along with the modulating redox axis of CD8+ T cells can also be a viable therapeutic option, as IL-21 is known to promote both Th17 and Tfh in SLE cells, and our study also indicates that priming with IL-21 can polarize CD8+ towards an inflammatory phenotype.